← Back to Search

Calcium Channel Blocker

Amlodipine for Hypertension

Phase 4
Waitlist Available
Research Sponsored by Prisma Health-Upstate
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through hospital stay, on average 2-5 days
Awards & highlights

Summary

This trial aims to determine if amlodipine is as effective as nifedipine ER in managing high blood pressure in postpartum women. Amlodipine is known for having fewer side effects and works by widening blood vessels to improve blood flow. Amlodipine is a long-acting calcium antagonist that effectively lowers blood pressure in patients with essential hypertension.

Eligible Conditions
  • Pregnancy-Induced Hypertension (PIH)

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through hospital stay, on average 2-5 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and through hospital stay, on average 2-5 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Length of stay

Side effects data

From 2019 Phase 4 trial • 44 Patients • NCT02034435
7%
Headache
4%
numbness
4%
Dizziness/Lightheadedness
4%
viral illness
4%
Low glucose
4%
Nausea
100%
80%
60%
40%
20%
0%
Study treatment Arm
Aim 1- Low Sodium
Aim 2- Amlodipine
Aim 2- Eplerenone
Aim 1- High Sodium

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: AmlodipineExperimental Treatment1 Intervention
Group II: Nifedipine ERActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Amlodipine
FDA approved

Find a Location

Who is running the clinical trial?

Prisma Health-UpstateLead Sponsor
85 Previous Clinical Trials
43,643 Total Patients Enrolled
1 Trials studying Hypertension
202 Patients Enrolled for Hypertension
~30 spots leftby Oct 2025